Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.
Albiruni Ryan Abdul Razak, MRCP, MBBCh, medical oncology lead, Sarcoma, Princess Margaret Cancer Centre and Mount Sinai Hospital, discusses initial findings from a phase 2 trial (NCT03851614) evaluating the utility of durvalumab (Imfinzi) in combination with olaparib (Lynparza) or cediranib (Recentin) in leiomyosarcoma.
Findings from the study demonstrated a 33% rate of disease stabilization in patients with leiomyosarcoma who received durvalumab in combination with olaparib or cediranib; however, the benefit was mainly observed with the olaparib-containing doublet, Abdul Razak says. Moreover, one patient who completed 1 year of durvalumab/olaparib and derived stable disease (SD) had a significant increase in CD8 T cells and macrophages compared with patients who derived clinical benefit with durvalumab/cediranib. Additionally, patients who received the olaparib-containing regimen experienced a significant reduction in tumor growth rate vs baseline, whereas patients who received the cediranib-containing doublet did not.
Additionally, tumor kinetic analysis could potentially identify patients who are likely to derive prolonged SD with treatment. Ultimately, more mature data are needed to determine the utility of these regimens in patients with leiomyosarcoma, Abdul Razak concludes.